Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Barasertib + Navitoclax |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Barasertib | AZD1152|AZD-1152 | Aurkb Inhibitors 21 | Barasertib (AZD1152) is a selective Aurora B kinase inhibitor, which induces cell cycle arrest (PMID: 17495131, PMID: 30540594). | |
| Navitoclax | ABT-263 | BCL-XL inhibitor 14 BCL2 inhibitor 29 | Navitoclax (ABT-263) is a BCL2, BCL-XL, and BCL-W inhibitor, which may enhance the efficacy of chemotherapeutics (PMID: 25787766, PMID: 32513939). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|